{"entity":{"id":"idea-bio1-barcoded-avatars-clonal-fitness","kind":"idea","name":"Barcode patient-derived tumours to watch which clones win under each drug","aka":[],"tldr":"Tag every cell in a patient's lab-grown tumour with a unique DNA label, give it a drug, and read the labels to see which cells survive. This predicts which resistant clone will emerge.","summary":"Lentiviral cellular barcoding of organoids or PDX models allows quantitative clonal tracking under therapy. Applied to patient avatars before treatment, it would measure the pre-existing resistant clone fraction and fitness under candidate drugs, prioritising combinations that suppress all high-fitness clones rather than the bulk.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Tumour heterogeneity and clonal evolution): Gerlinger et al., Intratumor heterogeneity and branched evolution (NEJM 2012)","url":"https://doi.org/10.1056/NEJMoa1113205"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["organoids","pdx-models","crispr-screens"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["resistance"],"trials":[],"people":[],"bottlenecks":["b-tumor-heterogeneity","b-preclinical-models"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Barcoded avatar clonal dynamics predict the dominant resistance clone found in the patient's progression biopsy in most cases, and drug combinations chosen to suppress all barcoded winners extend avatar time-to-regrowth compared with bulk-response-chosen combinations.","rationale":"Barcoding studies in cell lines and PDX (for example in breast and lung models) show that resistance often arises from rare pre-existing clones whose identity is stable and predictable, not from random de novo events.","test":"Barcode 30 patient-derived models with matched clinical follow-up, treat with the patient's actual regimen, and compare the barcoded winner genotype with the patient's progression biopsy.","maturity":"preclinical-evidence","actor":"research","cost":"medium","horizonYears":4},"route":"/ideas/idea-bio1-barcoded-avatars-clonal-fitness/","neighbours":{"technology":[{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/"},{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/"}],"term":[{"id":"resistance","kind":"term","name":"Drug resistance (primary and acquired)","route":"/terms/resistance/"}],"bottleneck":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/"}]}}